CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00661778
NCT00661778Phase 2Completed
CompareCT.gov

An Open Label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Docetaxel and Cisplatin on Progression-free Survival in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

Hoffmann-La Roche·interventional·Posted Apr 18, 2008·Updated Jul 10, 2014

In Brief

A Phase 2 clinical trial evaluating Bevacizumab, Cisplatin, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 50 participants across 14 sites.

Detailed Summary

This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m\^2, and cisplatin 75 mg/m\^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesSpain
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2008
Enrollment StartJul 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.2 years ago

Interventions

Bevacizumabdrug

Bevacizumab was supplied as a sterile liquid in glass vials.

Cisplatindrug

Bevacizumab was supplied as a sterile liquid in glass vials.

Docetaxeldrug

Bevacizumab was supplied as a sterile liquid in glass vials.